MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Hosts Virtual i-PfSPZ-C Meeting
231 malaria researchers, regulators and funders from 68 institutions located in 27 different countries met virtually to share plans, insights and data, all aiming to advance the development of whole sporozoite malaria vaccines.
EUMF Investment of €12.9M in Sanaria Highlighted in BioBuzz Article
On December 2nd, 2020, the European Union Malaria Fund’s (EUMF) investment of €12.9 million in Sanaria Inc. was highlighted in an BioBuzz article written by Alex Keown. The investment will fund the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine. Sanaria is the first and only U.S.-based company that has received funding from the EUMF! The full article can be accessed by this link.
Presentations by the Bioko Island Malaria Elimination Project at the annual meeting of the American Society of Tropical Medicine and Hygiene.
Sanaria is proud to showcase posters from BIMEP that were displayed during ASTMH 2020.
Sanaria’s CEO, Dr. Stephen L. Hoffman, awarded the Clara Southmayd Ludlow Medal at the American Society of Tropical Medicine and Hygiene’s annual conference
On November 15th, Dr. Stephen L. Hoffman was awarded the Clara Southmayd Ludlow Medal at the American Society of Tropical Medicine and Hygiene’s annual conference which recognizes honorees for inspirational and pioneering spirit, whose work represents success despite obstacles, and advances the field of tropical medicine. Clara Southmayd Ludlow was an entomologist with scientific zeal and tenacity who battled the odds of age, gender and skepticism of women in the sciences to advance the understanding of tropical medicine.
EU Malaria Fund: Sanaria to receive financing to develop Malaria vaccine
Sanaria to receive €12.9M for the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine from the EU Malaria Fund.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.